Overview

Safety and Efficacy of BFH772 in Psoriasis Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene